Analysis of survival and characteristics of patients with non-small cell lung carcinoma (NSCLC) stage IV depending on molecular markers

Conclusions: EGFR mutated in 10%, mostly in women and non-smokers, all of them adenocarcinoma. Low prevalence of the other mutations. Mutation of EGFR has better prognosis. In the multivariate analysis, the IVA vs IVB stage, ECOG, RT and treatment with ITK in mutated EGFR leads to a better prognosis.

Source: European Respiratory Journal - November 20, 2019 Category: Respiratory Medicine Authors: Andia Iturrate, J., Jimenez, P., Ansola, L., Saiz, M., Garcia, L., Gonzalez, B., Garay, E., Ansola, P. Tags: Lung cancer Source Type: research